

Wednesday 17 September 2014

10.30am	Registration opens
1.45pm-4.00pm	Opening Ceremony and Plenary Room: Macdonnell A-B Chairs: James Ward, Josh Davis and Annie Madden
1.50pm-1.55pm	Welcome To Country Ms Rosalie (Kumalie) Riley
1.55pm-2.00pm	Dignitary presentation Presenter to be advised
2.00pm-2.05pm	Dignitary presentation Presenter to be advised
2.05pm-2.10pm	Introduction by Representative of the 2014 Viral Hepatitis Conference Collaborating Organisations Conference Convenor and Associate Professor, James Ward, Deputy Program Lead for Aboriginal Health , Baker IDI, Alice Springs, NT, Australia
2.10pm-2.20pm	Auckland Statement - Report Card Helen Tyrrell, CEO, Hepatitis Australia, Canberra, ACT, Australia and John Hornell, Chief Executive Officer, Hepatitis Foundation of New Zealand
2.20pm-2.30pm	The importance of the principle of meaningful affected community engagement and the practical implications for a partnership approach Annie Madden, CEO, Australian Injecting & Illicit Drug Users League, ACT, Australia and Yvonne Drazic, PhD candidate, James Cook University, Cairns, QLD, Australia
2.30pm-2.50pm	Overview of the World Indigenous Peoples' Conference on Viral Hepatitis and Consensus Statement Associate Professor, James Ward, Deputy Program Lead for Aboriginal Health , Baker IDI, Alice Springs, NT, Australia and Professor Chris Cunningham, Chair, The Hepatitis Foundation of NZ, Wellington, New Zealand
2.50pm-3.20pm	From Data to Policy: Hepatitis B and Hepatitis C Prevention Policies in the United States Dr John Ward, Director, Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), USA
3.20pm-3.40pm	State of the Art – Interferon-free therapy for hepatitis C Dr Alex Thompson, Director, Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia
3.40pm-4.00pm	Addressing Hepatitis B through Community Action Alison Coelho, Manager Multicultural Health & Support Service, Centre for Culture, Ethnicity & Health, VIC, Australia
4.00pm-4.30pm	Afternoon Tea in Exhibition and Poster Area Macdonnell C Highlights from the upcoming HBV Mapping Report: Estimates of CHB diagnosis and monitoring by Medicare Local

Wednesday 17 September 2014

4.30pm-6.00pm	Cross-Track Symposium - Viral Hepatitis and Substance Use	4.30pm-6.00pm	Cross-Track Symposium - The challenges and possible solutions for addressing hepatitis B across key priority populations - Sponsored by Department of Health
	Room: Macdonnell A-B Chairs: Angella Duvnjak and Greg Dore		Room: Ellery A/D Chair: Bob Batey
4.30pm-4.45pm	Treatment for Hepatitis C virus infection among people who inject drugs in the opioid substitution setting: The ETHOS Study (Submission 98)	4.30pm-4.50pm	Epidemiology of chronic hepatitis B in key priority populations - similarities and differences
	Michelle Micallef		Dr Benjamin Cowie, VIDRL, Melbourne, VIC, Australia
4.45pm-5.00pm	Evaluation of two community-controlled peer support programs for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS Study, Australia (Submission: 97)	4.50pm-5.40pm	Panel Session - Commonalities and differences between the issues faced by Aboriginal and Torres Strait Islander peoples and people from culturally and linguistically diverse backgrounds Panel: Dr David Scrimgeour, Public Health Medical Officer, Aboriginal Health Council of SA, SA, Australia; Associate Professor, Gracelyn Smallwood, James Cook University, Townsville, QLD, Australia; Peter Waples-Crowe, Victorian Aboriginal Community Controlled Health Organisation, VIC, Australia; Associate Professor, James Ward, Deputy Program Lead for Aboriginal Health , Baker IDI, Alice Springs, NT, Australia; Dr Jacqui Richmond, Clinical Nurse Consultant, Royal Melbourne Hospital, VIC, Australia; Marina Suarez, Health Promotion Officer, Multicultural HIV and Hepatitis Service, NSW, Australia; Jack Wallace, Research Fellow, Australian Research Centre in Sex, Health and Society, Melbourne, VIC, Australia; and Dr Benjamin Cowie, VIDRL, Melbourne, VIC, Australia
5.00pm-5.15pm	Liverlife: A healthy liver campaign among people who inject drugs in the drug and alcohol setting (Submission 99)		
5.15pm-5.30pm	Liver Mates: Why must the affected community be supported to lead on the development and delivery of hepatitis C treatment and healthy liver interventions? (Submission 152)		
	Michelle Micallef		
	Nicky Bath		
5.30pm-6.00pm	Panel Discussion Angella Duvnjak, AIVL; Greg Dore, Kirby Institute; Michelle Micallef, Kirby Institute; Carla Treloar, Centre for Social Research in Health; Nicky Bath, NSW Users & AIDS Association's; Adrian Dunlop, University of Newcastle; and Hope Everingham, NSW Users & AIDS Association	5.40pm-6.00pm	Recommendations for action for addressing chronic hepatitis B across key priority populations
			Panel: Dr David Scrimgeour, Public Health Medical Officer, Aboriginal Health Council of SA, SA, Australia; Associate Professor, Gracelyn Smallwood, James Cook University, Townsville, QLD, Australia; Peter Waples-Crowe, Victorian Aboriginal Community Controlled Health Organisation, VIC, Australia; Associate Professor, James Ward, Deputy Program Lead for Aboriginal Health , Baker IDI, Alice Springs, NT, Australia; Dr Jacqui Richmond, Clinical Nurse Consultant, Royal Melbourne Hospital, VIC, Australia; Marina Suarez, Health Promotion Officer, Multicultural HIV and Hepatitis Service, NSW, Australia; Jack Wallace, Research Fellow, Australian Research Centre in Sex, Health and Society, Melbourne, VIC, Australia; and Dr Benjamin Cowie, VIDRL, Melbourne, VIC, Australia
6.00pm-7.30pm	Welcome Reception & Poster Viewing Evening, Transport will be provided back to hotels Macdonnell C		
	Launches from sector organisations to be held here ASHM - B Positive NSW Users and AIDS Association - To launch the Community Consultation Rapid Scoping Project among Aboriginal People who Inject Drugs Report ASHM - Launch of the HIV, Viral Hepatitis and STIs Guide for Primary Care 2014 edition		

Thursday 18 September 2014

7.30am	Registration						
8.30am-9.30am	Conference Plenary 2: Central issues in Global access for Hepatitis C treatment						
8.30am-9.00am	Room: Macdonnell A-B Chairs: Greg Dore and Helen Tyrrell						
8.30am-9.00am	Brave New World for Hepatitis C - How do we ensure resource limited countries aren't left behind Professor Margaret Hellard, Head, Centre for Population Health, Burnet Institute,; Head of Hepatitis Services, Infectious Diseases Unit, The Alfred Hospital, Melbourne, VIC, Australia						
9.00am-9.30am	Advocating for access to HCV treatment: Community experiences from Asia Giten Khwairakpam - Community and Policy Project Manager, amfAR's TREAT Asia program, Bangkok, Thailand						
9.30am-10.20am	Morning Tea in Exhibition and Poster Area Macdonnell C						
9.40am-10.10am	Surveillance Data Release from the Kirby Institute and Centre for Social Research in Health Ellery Room A/D						
10.20am-11.50am	Proffered Paper Session: Epi, PH & Prevention - Trends and Trajectories	10.20am-11.50am	Proffered Paper Session: Clinical Care - HBV	10.20am-11.50am	Proffered Paper Session: Community & Social Research - Preventing Viral Hepatitis	10.20am-11.50am	Proffered Paper Session: Community & Social Research - Engaging Community
	Room: Macdonnell A-B Chairs: Nicole Allard and Sushena Krishnaswamy		Room: Ellery Room A/D Chairs: Saliya Hewagama and Jill Benson		Room: Ellery Room B Chairs: Charles Henderson and Kerry Paterson		Room: Ellery Room C Chairs: Giten Khwairakpam and Helen Tyrrell
10.20am-10.35am	Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian Setting, 1996-2012 (Submission 76) Jason Grebely	10.20am-10.35am	The role of financial incentives in developing hepatitis B immunity following accelerated vaccination among people who inject drugs in Sydney, Australia: Randomised controlled trial (Submission102) Carolyn Day	10.20am-10.35am	Everyday objects and injecting: Why do people who inject drugs in sexual partnerships 'run out' of sterile equipment? (Submission 30) Suzanne Fraser	10.20am-10.38am	So Heppy Together: Perceptions of peers and its impact on south-south hepatitis C capacity building collaborations (Submission 176) Ele Morrison
10.35am-10.50am	Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study (Submission 21) Bethany White	10.35am-10.50am	Treating Immune-tolerant HBV: Factors Associated with Significant Decline in HBeAg and HBsAg Levels (Submission 124) Gillian Rosenberg	10.35am-10.50am	Negotiating risk, navigating relationship: accounts of needle-syringe sharing within romantic partnerships (Submission 89) Jake Rance		
10.50am-11.05am	Low rates of re-infection long-term following recently acquired HCV in the Australian Trial of Acute Hepatitis C: the ATAHc Recall study (Submission 107) Joseph Doyle	10.50am-11.05am	Use of Antiviral therapy in Pregnant Women with Hepatitis B in the Top End of the Northern Territory (Submission 103) Catherine Marshall	10.50am-11.00am	Innovation in hepatitis C prevention: A trial of symbiotic and pleasure-based messages with NSP staff and clients (Submission 77) Carla Treloar	10.38am-10.56am	Learning by doing- CALD youth as hepatitis B community educators (Submission 144) Debbie Nguyen

Thursday 18 September 2014

11.05am-11.13am	Trends in chronic hepatitis B diagnosis In Australia, 2009-2013 (Submission 183) Jennifer MacLachlan	11.05am-11.20am	Improving quality of care for people living with hepatitis B in primary care: preliminary data from the Integrated Hepatitis B Service (Submission 165) Tracey Cabrie	11.00am-11.15am	Peer Education the forgotten tool for fighting viral hepatitis (Submission 180) Yvonne Samuel	10.56am-11.14am	Hepatitis workforce development: A decade of learning The ABCs (Submission 59) Lana Pocock
11.13am-11.21am	Trends in relative survival of patients diagnosed with Hepatocellular Carcinoma: A population-based cohort study (Submission 38) Hla-Hla (Rosie) Thein	11.20am-11.35am	Management of Hepatitis B during pregnancy at Geelong Hospital: a retrospective review (Submission 35) Sarah Beynon	11.15am-11.30am	Building on Shaky Ground - a Peer Educator and Peer Leader Program in the ACT (Submission 185) Sione Crawford and Peter Parkes	11.14am-11.32am	Improving chlamydia and hepatitis C awareness through a sexual and reproductive health education program for Aboriginal and Torres Strait Islander students in Victorian secondary schools (Submission 83) Bradley Whitton
11.21am-11.36am	Time to Hepatocellular Carcinoma after notification of hepatitis B or C infection: A population-based cohort study,1992-2007 (Submission 91) Maryam Alavi	11.35am-11.50am	Discussion	11.30am-11.40am	Acquiring hepatitis C in prison: A qualitative study of the HITSP cohort (Submission 82) Carla Treloar	11.32am-11.50am	Discussion
11.36am-11.50am	Discussion			11.40am-11.50am	Discussion		
11.50am-12.50pm	Lunch in Exhibition and Poster Area Macdonnell C						
12.10pm-12.40pm	Research Consultation: Hepatitis C and couples who inject drugs Room: Ellery Room B The Centre for Social Research in Health is leading a large, NHMRC-funded research project exploring the reasons behind hepatitis C transmission between sexual partners who inject drugs, strategies used use to manage hepatitis C-related risk both within partnerships and with others, and relationship issues and dynamics that shape injecting practices in sexual partnerships. What can we learn from participants' insights and strategies, and how might we build upon this for the future? During this meeting the researchers will briefly introduce the main issues the project has identified before opening up the session for general discussion. We welcome people living with or affected by hepatitis C, front-line workers, clinicians, service managers and policy-makers to engage with this important and complex topic. Presented by Professor Carla Treloar and Jake Rance (CSRH, UNSW Australia) and A/Professor Suzanne Fraser (Curtin University).						
12.50pm-1.50pm	Conference Plenary 3: Hep B in the past and future Room: Macdonnell A-B Chairs: Scott Bowden and Bob Batey						
12.50pm-1.20pm	Of bats and men: species specificity of hepadnaviral infection Dr Dieter Glebe, Head, National Reference Centre for Hepatitis B and D viruses, Institute of Medical Virology, Justus-Liebig University Giessen, Germany						
1.20pm-1.50pm	HBV Reactivation: Playing with fire Professor Maggie Bassendine, Professor of Hepatology, Institute of Cellular Medicine, Newcastle University, UK						

Thursday 18 September 2014

1.50pm-2.00pm	Movement to Concurrent Sessions Macdonnell A-B OR Ellery A/D	
2.00pm-3.30pm	Cross-Track Symposium -Human Rights, The Law and Discrimination Room: Macdonnell A-B Chairs: Carla Treloar and Anna Roberts	2.00pm-3.30pm Cross-Track Symposium - Hepatitis and Liver Cancer Room: Ellery A/D Chairs: Stephen Locarnini and Benjamin Cowie
2.00pm-2.10pm	Introduction and overview: why are human rights, the law and discrimination important in viral hepatitis Annie Madden, CEO, Australian Injecting & Illicit Drug Users League, ACT, Australia	2.00pm-2.15pm How does hepatitis cause liver cancer? Dr Nadia Warner, Senior Medial Scientist, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
2.10pm-2.25pm	Vignette 1 – Prevention of viral hepatitis within prisons Dr Helen Watchirs, ACT Human Rights Commissioner, ACT, Australia	2.15pm-2.30pm Novel diagnostics in viral hepatitis – how can they address the liver cancer burden? Dr Scott Bowden , Senior Medial Scientist, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
2.25pm-2.40pm	Vignette 2 – Australia’s role in country of origin for hepatitis B Nafisa Yussf, Community Development Officer, Centre for Culture, Ethnicity and Health, VIC, Australia	2.30pm-2.45pm Liver cancer in the Northern Territory – recent data and how it can guide diagnosis and management Dr Josh Davis, Staff Specialist, John Hunter Hopsital, Newcastle, NSW, Australia
2.40pm-2.55pm	Vignette 3 – Workplace discrimination Lyn Payne, Senior Solicitor, NSW Legal Aid Commission, Human Rights Team, NSW, Australia	2.45pm-3.00pm The National Liver Cancer Prevention Policy and future policy directions for Australian Cancer Councils Dr Monica Robotin, Medical Director, Cancer Council, NSW, Australia
2.55pm-3.10pm	Vignette 4 – The future of hepatitis C treatment Helen Tyrrell, CEO, Hepatitis Australia, ACT, Australia	3.00pm-3.25pm Panel Discussion Dr Nadia Warner, Dr Scott Bowden, Dr Josh Davis, Chris Enright, Professor Stephen Locarnini, Dr Benjamin Cowie
3.10pm-3.30pm	Panel Discussion Annie Madden, Dr Helen Watchirs, Nafisa Yussf, Lyn Payne, Helen Tyrrell, Professor Carla Treloar and Anna Roberts	3.25pm-3.30pm Launch - Liver cancer resource for people affected by primary liver cancer in four languages Dr Monica Robotin, Medical Director, Cancer Council, NSW, Australia
3.30pm-4.00pm	Afternoon Tea in Exhibition & Poster Viewing Area Macdonnell C	

Thursday 18 September 2014

4.00pm-5.30pm	Symposia Session 1: Epi, PH & Prevention - Cascade of Care (Access to care)	4.00pm-5.30pm	Symposia Session 2: Clinical Care - AHA Nursing Session	4.00pm-5.30pm	Symposia Session 3: Community & Social Research - Connecting to Care Workshop	4.00pm-5.30pm	Symposia Session 4: Basic Science - HCV1 - Curing HCV: What will the virus try next?
	Room: Macdonnell A-B Chairs: Vanessa Towell and Mark Stoove		Room: Ellery Room A/D Chairs: Megan Phelps and Eleanor Hooke		Room: Ellery Room B Chairs: Helen Tyrrell and Carla Treloar		Room: Ellery Room C Chairs: Scott Bowden and Tanya Applegate
4.00pm-4.20pm	The cascade of care for people living with chronic hepatitis B: access to treatment and monitoring in Australia (Submission 121) Nicole Allard	4.00pm-4.25pm	Successes and challenges of delivering hepatitis C nursing care in the Top End Rebecca Katiforis, Clinical Nurse Consultant, Northern Territory Government, NT, Australia	4.00pm-4.05pm 4.05pm-4.10pm 4.10pm-4.15pm 4.15pm-4.20pm	Chronic Hepatitis Primary Care Pathway Judith Bevan, Senior Policy and Planning Officer, Department of Health WA, Australia Livermates Nicky Bath, CEO, NSW Users and AIDS Association, NSW, Australia B Positive Program Dr Monica Robotin, Medical Director, Cancer Council, NSW, Australia Indigenous hepatitis B App Josh Davis and Jane Davies, Menzies School of Health Research, NT, Australia	4.00pm-4.15pm 4.15pm-4.30pm	Genetic determinants of HCV treatment outcome Alex Thompson QUAC: Q80K mUtation prevalence in an Australian hepatitis C population (Submission 131) Adrian Teck Leng Ong
4.20pm-4.40pm	The HCV Care Cascade: Mapping the HCV clinical care pathway in Australia Jason Grebely, Senior Lecturer, Kirby Institute, NSW, Australia	4.25pm-4.50pm	From Treatment to Peer Worker Frances Tenison, Clinical Nurse Consultant, A W Morrow Gastro and Liver Centre, Royal Prince Alfred Hospital, NSW, Australia and Damien House, Aboriginal Peer Support Health Worker, Sydney Local Health District, NSW, Australia	4.20pm-4.40pm	Breakout 1 - Hep B	4.30pm-4.45pm	Hepatitis C virus can accumulate mutations that confer resistance to a novel broadly neutralizing antibody MAb24 (Submission 66) Jun Gu
4.40pm-4.50pm	Cascade of care for Aboriginal and Torres Strait Islander people Associate Professor, James Ward, Deputy Program Lead for Aboriginal Health, Baker IDI, Alice Springs, NT, Australia	4.50pm-5.05pm	Hepatology Nursing In The Era of Expanding Hepatitis C Evidence (Submission 57) Dr Jacqui Richmond, Clinical Nurse Consultant, Royal Melbourne Hospital, VIC, Australia	4.40pm-5.00pm	Breakout 2 - Hep C	4.45pm-5.00pm	Preclinical development of a prophylactic vaccine for Hepatitis C virus using a novel E2 core domain (Submission 65) Heidi Drummer
4.50pm-5.00pm	Cultural lenses – Pathways to care from prevention to treatment Enaam Oudih, Practice Manager, Multicultural Services, SA, Australia						

Thursday 18 September 2014

5.00pm-5.10pm	A trickle not a cascade – caring for people who inject drugs Jude Byrne, Senior Project Worker, Australian Injecting & Illicit Drug Users League, ACT, Australia	5.05pm-5.30pm	Hepatitis C in SA from Tertiary to Primary Care Rosalie Altus, Clinical Practice Consultant, Viral Hepatitis Liaison Nurse, Flinders Medical Centre, SA, Australia	5.00pm-5.30pm	Discussion	5.00pm-5.15pm	Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C (Submission 101) Silvana Gaudieri
5.10pm-5.30pm	Panel Discussion					5.15pm-5.30pm	Cytolytic DNA vaccines enhance immunity to hepatitis C virus (Submission 19) Eric Gowans
5.30pm	Transfers to Conference Dinner, The Quarry						
6.00pm-10.00pm	Conference Dinner, The Quarry						

Friday 19 September 2014

6.30am	Registration						
7.00am-8.50am	The inaugural ALA Symposium sponsored by BMS Chronic Hepatitis C (CHC): current and future impact on burden of disease Room: Macdonnell C Chair: Amany Zekry						
7.00am-7.20am	Breakfast served						
7.20am-7.30am	Welcome and Introductions Associate Professor Amany Zekry, St George's Hospital, Sydney, NSW, Australia						
7.30am-7.50am	Stratifying risk of complications in CHC related liver cirrhosis Associate Professor Amany Zekry, St George's Hospital, Sydney, NSW, Australia						
7.50am-8.10am	HCC burden- ongoing screening in cirrhotics who clear the virus Associate Professor Simone Strasser, Royal Prince Alfred Hospital, Sydney, NSW, Australia						
8.10am-8.30am	The impact of DAA on the burden of HCV related liver cirrhosis Professor Stuart Roberts, The Alfred Hospital, Melbourne, VIC, Australia						
8.30am-8.45am	Panel Discussion Associate Professor Amany Zekry, Associate Professor Simone Strasser, and Professor Stuart Roberts						
8.45am-8.50am	Closing remarks and thanks Associate Professor Amany Zekry, St George's Hospital, Sydney, NSW, Australia						
8.50am-9.00am	Movement to next concurrent sessions						
9.00am-10.30am	Symposia Session: Clinical Care - New challenges in the management of hepatitis C in the DAA era Room: Macdonnell A-B Chairs: Josh Davis and Amany Zekry	9.00am-10.30am	Symposia Session : Epi, PH & Prevention - Approaches to hepatitis B and hepatitis C prevention in rural & regional settings Room: Ellery Room A/D Chairs: Lisa Maher and Mark Stoove	9.00am-10.30am	Symposia Session: Community & Social Research - Working with CALD communities in Viral Hepatitis Room: Ellery Room B Chairs: Zhihong Gu and Alison Coelho	9.00am-10.30am	Symposia Session: Basic Science - HBV 1: Chronic HBV infection: Factors influencing disease progression Room: Ellery Room C Chairs: Peter Revill and Eric Gowans
9.00am-9.30am	Hepatitis C genotype 3 infection – Is it the new Genotype 1? Professor Maggie Bassendine - Professor of Hepatology, Institute of Cellular Medicine, Newcastle University, UK	9.00am-9.10am	NSP in urban, rural and regional settings – distribution models and viral hepatitis prevention coverage Jenny Iversen, Lecturer, Kirby Institute, NSW, Australia	9.00am-9.15am	Strengthening Community Responses to Hepatitis B (Submission 42) Roslyn Le and William Mude	9.00am-9.30am	Model + host molecular effectors of HBV control Dr Marc Pellegrini, Infectious diseases physician and Laboratory Head, Infection and Immunity Division, Walter and Eliza Hall Institute, Melbourne, VIC, Australia
		9.10am-9.20am	Providing OST in rural/regional settings – What are the opportunities to enhance viral hepatitis prevention and care Conjoint Associate Professor, Adrian Dunlop, Faculty of Health and Medicine, University of Newcastle, NSW, Australia	9.15am-9.30am	No vaccination against discrimination: Chinese Viral Hepatitis Needs Assessment. (Submission 47) Jack Wallace		

9.30am-10.00am	Treating hepatitis C patients with advanced liver disease and post liver transplantation in the DAA era Associate Professor Simone Strasser, Royal Prince Alfred Hospital, Sydney, NSW, Australia	9.20am-9.35am	Integrated viral hepatitis primary care models in rural and regional settings – Insights from the Kirketon Road Centre Dr Phillip Read, Staff Specialist, Kirketon Road Centre, NSW, Australia	9.30am-9.45am	Tradition and innovation working hand in hand: Engaging communities affected by chronic hepatitis B (Submission 61) Marina Suarez	9.30am-10.00am	Novel therapeutic that kills HBV infected cells Dr Marc Pellegrini, Infectious diseases physician and Laboratory Head, Infection and Immunity Division, Walter and Eliza Hall Institute, Melbourne, VIC, Australia
		9.35am-9.50am	Much more needs to be done for Aboriginal people who inject drugs – Findings from a NSW community consultation Nicky Bath, CEO, NSW Users and AIDS Association (NUAA), NSW, Australia	9.45am-10.00am	Know Your Hepatitis B Status (with African communities) (Submission 170) Enaam Oudih		
		9.50am-10.05am	Promoting or preventing harm?: integrating viral hepatitis prevention in Aboriginal Community Controlled Health Organisation services Peter Waples-Crowe, Victorian Aboriginal Community Controlled Health Organisation, VIC, Australia				
10.00am-10.30am	Expanding access to hepatitis C treatment through primary care: challenges and opportunities Professor Greg Dore, Head, Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW, Australia	10.05am-10.30am	Facilitated panel discussion with presenters	10.00am-10.15am	Chronic Hepatitis B Education in the North Queensland Hmong Community: Positive Change through Process and Perseverance (Submission 159) Yvonne Drazic	10.00am-10.15am	Spliced HBV genomes and truncated surface proteins are associated with ground glass hepatocytes, the neoplastic precursors to HBV associated hepatocellular carcinoma (Submission 75) Nadia Warner
				10.15am-10.30am	Discussion		
10.30am-11.00am	Morning Tea in Exhibition and Poster Area Macdonnell C						

11.00am-12.30pm	Proffered Paper Session: Epi, PH & Prevention - Prevention and Care programs Room: Macdonnell A-B Chairs: Tracey Hutt and Annie Balcomb	11.00am-12.30pm	Proffered Paper Session: Clinical Care - HCV Room: Ellery Room A/D Chairs: Jane Davies and Sushena Krishnaswamy	11.00am-12.30pm	Proffered Paper Session: Community & Social Research - Living with Viral Hepatitis Room: Ellery Room B Chairs: Jake Rance and Annie Madden	11.00am-12.30pm	Proffered Paper Session: Basic Science -HBV 2: The HBV journey: Virus entry to viral variants Room: Ellery Room C Chairs: Heidi Drummer and Margaret Hellard
11.00am-11.15am	Trends of hepatitis B surface antigen carriage in central Nepal: A reality check from a mass screening after nationwide HBV vaccination (Submission 56) Dhruba Acharya	11.00am-11.15am	Factors associated with hepatitis C virus RNA levels in early acute and early chronic infection: The InC3 Study (Submission 71) Behzad Hajarizadeh	11.00am-11.15am	Psychosocial health among people with chronic hepatitis B in Australia (Submission 54) Jacqui Richmond	11.00am-11.30am	Bile acids and hepatitis B virus compete for the Na⁺-dependent taurocholate cotransporting polypeptide (NTCP) Dr Dieter Glebe, Head, National Reference Centre for Hepatitis B and D viruses, Institute of Medical Virology, Justus-Liebig University Giessen, Germany
11.15am-11.30am	Estimating uptake of treatment for chronic hepatitis B infection across Australia (Submission 178) Jennifer MacLachlan	11.15am-11.30am	Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS Study (Submission 88) Maryam Alavi	11.15am-11.30am	Experiences of ageing and living with hepatitis C: Reflections from a cohort of people who inject drugs (Submission 134) Peter Higgs		
11.30am-11.45am	Evaluation of New South Wales Hepatitis B Prescriber Program - Challenges and Successes (Submission 74) Vanessa Towell	11.30am-11.45am	Regression of advanced fibrosis following virological response to anti-HCV therapy (Submission 106) Marianne Martinello	11.30am-11.45am	Hepatitis C and Ageing: Perspectives from the clinical, community and government sectors (Submission 40) Jacqui Richmond	11.30am-11.45am	The role of genotype in HBV replication and natural history (Submission 117) Peter Revill
11.45am-12.00pm	Characteristics of chronic hepatitis B infection in SW Sydney: clinical correlates and policy implications (Submission 145) Monica Robotin	11.45am-12.00pm	Efficacy and safety of Daclatasvir in combination with Asunaprevir (DCV+ASV) in cirrhotic and non-cirrhotic patients with HCV genotype 1B: Results of the Hallmark Dual Study (Submission 31) Stuart Roberts	11.45am-12.00pm	Yarning about Hep C; Aboriginal Victorians telling our stories about living with Hep C (Submission 87) Peter Waples-Crowe and Andrew Bamblett	11.45am-12.00pm	Hepatitis B Virus in African immigrants living in Australia (Submission 162) Rosalind Edwards
12.00pm-12.15pm	Champions and challenges in Australia's response to Blood Borne Viruses (Submission 161) Kevin Marriott	12.00pm-12.15pm	Treating hepatitis C: Does gender matter? (Submission 188) Anna Olsen	12.00pm-12.15pm	Your Mob, My Mob, Our Mob (YMMOM) Peer Education Project (Submission 130) Kerry Walker and Bonny Briggs	12.00pm-12.15pm	Directly Cytopathic Drug Resistant HBV Variants (Submission 204) Danni Colledge
12.15pm-12.30pm	Discussion	12.15pm-12.30pm	Discussion	12.15pm-12.30pm	Discussion	12.15pm-12.30pm	Use of Biomarkers to Monitor HBV Therapy Scott Bowden
12.30pm-1.30pm	Lunch in Exhibition and Poster Area Macdonnell C						

1.30pm-3.00pm	Proffered Paper Session: Epi, PH & Prevention - Priority Populations Room: Macdonnell A-B Chairs: Benjamin Cowie and Steven Tong	1.30pm-3.00pm	Proffered Paper Session: Clinical Care - Non-tertiary sites and models of care for HCV Room: Ellery A/D Chairs: Suresh Sharma and Stuart Roberts	1.30pm-3.00pm	Proffered Paper Session: Community & Social Research - Facilitating access to treatment Room: Ellery B Chairs: Carla Treloar and Jack Wallace	1.30pm-3.00pm	Proffered Paper Session: Basic Science- HCV 2 : Molecular and social networks: informing HCV treatment Room: Ellery C Chairs: Silvana Gaudieri and Mark Douglas
1.30pm-1.45pm	Hepatitis B knowledge among people with chronic hepatitis B in Australia (Submission 52) Behzad Hajarizadeh	1.30pm-1.45pm	Trends in health services utilization attributable to Hepatocellular Carcinoma: A population-based cohort study (Submission 141) Hla-Hla (Rosie) Thein	1.30pm-1.45pm	Psychosocial factors influencing successful interferon-based hepatitis C treatment outcomes (Submission 138) Victoria Sublette	1.30pm-2.00pm	Hepatitis C treatment as prevention in people who inject drugs – what is the role of the injecting network? Professor Margaret Hellard, Head, Centre for Population Health, Burnet Institute,; Head of Hepatitis Services, Infectious Diseases Unit, The Alfred Hospital, Melbourne, VIC, Australia
1.45pm-1.53pm	Automatic dispensing machines: No evidence of a honey-pot effect (Submission 100) Bethany White	1.45pm-2.00pm	Pilot for a community-based assessment and support programme for hepatitis C in New Zealand (Submission 069) John Hornell	1.45pm-2.00pm	Fibroscan Testing as a Community Engagement Strategy (Submission 25) Erin Devine		
1.53pm-2.01pm	Increasing the Victorian ACCHO response to injecting drugs and hepatitis C prevention (Submission 45) Peter Waples-Crowe	2.00pm-2.15pm	No prejudice! Being a prisoner, indigenous or having a psychiatric illness should not limit access to treatment for chronic hepatitis c infection. (Submission 27) James Elliott	2.00pm-2.15pm	Evaluation of “The hepatitis B story” – an educational resource to use in discussion with people who have low health literacy (Submission 123) Gabrielle Bennett	2.00pm-2.15pm	Phylogenetic clustering of Hepatitis C among street-involved youth in Vancouver, Canada (Submission 150) Evan Cunningham
2.01pm-2.09pm	The impact of overseas hepatitis B vaccination programs on the future burden of hepatitis B in Australia (Submission 158) Zoe Stephens						
2.09pm-2.24pm	Incident hepatitis B infection and immunisation uptake in Australian prison inmates (Submission 49) Luke McCredie	2.15pm-2.30pm	What makes a community-based HCV treatment program acceptable to clients? Insights from health care providers and clients (Submission 20) Julie Mooney-Somers	2.15pm-2.30pm	Looking Beyond the Bars – The first hepatitis C treatment program in QLD for women in custody (Submission 122) Jodie Walton	2.15pm-2.30pm	Molecular epidemiology of hepatitis C virus infections among people who inject drugs in Vancouver, Canada (Submission 126) Brendan Jacka
2.24pm-2.39pm	Can primary health care identify the diverse population living with chronic hepatitis B? (Submission 191) Margaret Hellard	2.30pm-2.45pm	Treating Hepatitis C in Primary Care: Results from a Pilot Program (Submission 79) David Baker	2.30pm-3.00pm	Discussion	2.30pm-2.45pm	Factors associated with phylogenetic clustering in of acute hepatitis C virus infection in Australia (Submission 63) Tanya Applegate
2.39pm-3.00pm	Discussion	2.45pm-3.00pm	Discussion			2.45pm-3.00pm	Patterns of hepatitis C virus RNA levels during acute infection: The INC³ Study (Submission 70) Behzad Hajarizadeh

3.00pm-3.30pm	Afternoon Tea in Exhibition and Poster Area Macdonnell C
3.30pm-5.00pm	Closing Plenary 4 - Eradication of hepatitis debates Room: Room: Macdonnell A-B Chairs: Scott Bowden and Carla Treloar
3.30pm-4.10pm	Debate - Despite the availability of effective treatments and vaccination for hepatitis B, we should prioritise funding for research to find a cure Facilitator: Dr Scott Bowden, Senior Medical Scientist, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia Affirmative – Dr Dieter Glebe, Head, National Reference Centre for Hepatitis B and D viruses, Institute of Medical Virology, Justus-Liebig University Giessen, Germany; Melanie Eagle, CEO, Hepatitis Victoria, Melbourne, VIC, Australia; and Professor Maggie Bassendine, Professor of Hepatology, Institute of Cellular Medicine, Newcastle University, UK Negative – Dr Benjamin Cowie, Physician & Epidemiologist, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia; Yvonne Drazic, PhD candidate, James Cook University, Cairns, QLD, Australia; and Dr Jill Benson, Medical Director, Kakarrara Wilurrara Health Alliance, SA, Australia
4.10pm-4.50pm	Debate - Hepatitis C vaccine development is still required in the era of vastly improved treatment Facilitator: Professor Carla Treloar, Deputy Director, Centre for Social Research in Health, Sydney, NSW, Australia Affirmative - Dr John Ward - Director, Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), USA; Helen Tyrrell, CEO, Hepatitis Australia, ACT, Australia; and Professor Kimberly Page, Professor & Chief, University of New Mexico Health Sciences Center, New Mexico, USA Negative - Associate Professor, James Ward, Deputy Program Lead for Aboriginal Health , Baker IDI, Alice Springs, NT, Australia; Charles Henderson, National Manager, NZ Needle Exchange Programme, Christchurch, New Zealand; and Professor Greg Dore, Head, Viral Hepatitis Clinical Research Program, The Kirby Institute, UNSW, Australia
4.50pm-5.00pm	Wrap Up and Conference Close Dr Scott Bowden and Professor Carla Treloar
5.00pm	Conference End
5.30pm-8.00pm	Informal BBQ Lasseters Hotel Pool Area